Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 7/20 | 0.57 |
| ▸ | HTR2C | P28335 | 2/20 | 0.56 |
| ▸ | HTR2B | P41595 | 1/20 | 0.56 |
| ▸ | MPO | P05164 | 1/20 | 0.52 |
| ▸ | HTR1D | P28221 | 7/20 | 0.50 |
| ▸ | HTR1B | P28222 | 7/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21227358 | 0.89 | HTR2A (0.57) | HTR2AHTR2CHTR2BMPOHTR1D | |
| SCHEMBL32669409 | 0.77 | DRD4 (0.64) | HTR2AHTR2CHTR2BHTR1AMAPK1 | |
| SCHEMBL32669452 | 0.76 | DRD4 (0.63) | HTR2AHTR2CHTR2BHTR1AMAPK1 | |
| SCHEMBL6363395 | 0.76 | DRD4 (0.63) | HTR2AHTR2CHTR2BHTR1AMAPK1 | |
| SCHEMBL733629 | 0.76 | HTR2A (0.94) | HTR2AHTR2CHTR2BMPOHTR1D | |
| SCHEMBL29543272 | 0.76 | HTR2A (0.94) | HTR2AHTR2CHTR2BMPOHTR1D | |
| SCHEMBL31036160 | 0.75 | HTR2A (0.54) | HTR2AHTR2CHTR2BMPOHTR1D | |
| SCHEMBL3212708 | 0.75 | HTR2A (0.54) | HTR2AHTR2CHTR2BMPOHTR1D | |
| SCHEMBL734226 | 0.75 | HTR2A (0.91) | HTR2AHTR2CHTR2BMPOHTR1D | |
| SCHEMBL32669458 | 0.75 | HTR2A (0.91) | HTR2AHTR2CHTR2BMPOHTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029629-A1 | ACYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-02-04 | — | — | US | disclosed |
| US-20100029629-A1 | ACYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-02-04 | — | — | US | disclosed |
| US-20100029629-A1 | ACYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-02-04 | — | — | US | disclosed |
| WO-2010011546-A2 | ACYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-01-28 | — | — | WO | disclosed |
| WO-2010011546-A2 | ACYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029629-A1 | ACYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | HTR6, HTR1A, HTR5A | HTR2A 8/4885HTR2C 7/4885HTR2B 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.